Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$33.55 ▲ +0.60
(+1.82%)
MKT CAP: $357.2M • VOL: 96.5K
52W L $15 52W H $910
ROARABLE / RQD
E • 34/100
PIOTROSKI
1 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$28
MEDIAN
$38
MEAN
$38
HIGH
$46
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE IRLA TAPE
IRLA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $40.60 | $38.58 | 2025-02-14 | $30.53 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $42.27 | $39.59 | 2025-02-06 | $31.54 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $38.25 | $36.91 | 2025-01-29 | $32.21 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $34.22 | — | 2025-01-17 | $32.88 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $29.52 | $31.87 | 2025-01-09 | $29.86 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $39.92 | $34.89 | 2024-12-18 | $29.19 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $32.54 | $33.89 | 2024-12-04 | $31.20 | -4.3% | 48% | C |